Opinion

Video

Role of Biomarkers in Graft-vs-Host Disease

Author(s):

Hana Safah, MD,Corey S. Cutler, MD, MPH, FRCPC

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

Related Videos
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Guru P. Sonpavde, MD
Related Content
Zanubrutinib in Newly Diagnosed CLL/SLL | Image Credit: © Свет Лана – stock.adobe.com
December 9th 2024

Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Chronic Lymphocytic Leukemia | Image Credit: © LASZLO– stock.adobe.com
December 9th 2024

Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

DLBCL | Image credit: ©Nittaya– stock.adobe.com
December 9th 2024

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL

Chronic Lymphocytic Leukemia | Image Credit: © LASZLO– stock.adobe.com
December 8th 2024

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL